PL3400217T3 - L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna - Google Patents
L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystalicznaInfo
- Publication number
- PL3400217T3 PL3400217T3 PL17700392T PL17700392T PL3400217T3 PL 3400217 T3 PL3400217 T3 PL 3400217T3 PL 17700392 T PL17700392 T PL 17700392T PL 17700392 T PL17700392 T PL 17700392T PL 3400217 T3 PL3400217 T3 PL 3400217T3
- Authority
- PL
- Poland
- Prior art keywords
- hydroxypropylthiazolidinocarboxyamide
- valinate
- salt
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662274674P | 2016-01-04 | 2016-01-04 | |
| US14/987,586 US9447055B1 (en) | 2016-01-04 | 2016-01-04 | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| US201662395664P | 2016-09-16 | 2016-09-16 | |
| US201662407918P | 2016-10-13 | 2016-10-13 | |
| PCT/EP2017/050101 WO2017118641A1 (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
| EP17700392.8A EP3400217B1 (en) | 2016-01-04 | 2017-01-04 | L-valinate of hydroxypropylthiazolidine carboxamide derivative, its salt and crystal form thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3400217T3 true PL3400217T3 (pl) | 2022-07-04 |
Family
ID=57799697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17700391T PL3397622T3 (pl) | 2016-01-04 | 2017-01-04 | Jednoczesne podawanie alfa-aminoestrowej pochodnej hydroksypropylotiazolidynokarboksyamidu i środka tokolitycznego |
| PL17700392T PL3400217T3 (pl) | 2016-01-04 | 2017-01-04 | L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17700391T PL3397622T3 (pl) | 2016-01-04 | 2017-01-04 | Jednoczesne podawanie alfa-aminoestrowej pochodnej hydroksypropylotiazolidynokarboksyamidu i środka tokolitycznego |
Country Status (25)
| Country | Link |
|---|---|
| EP (4) | EP3397622B1 (pl) |
| JP (6) | JP6933322B2 (pl) |
| KR (3) | KR20180100120A (pl) |
| CN (1) | CN108779087A (pl) |
| AU (5) | AU2017205670B2 (pl) |
| CA (2) | CA3009573A1 (pl) |
| CY (2) | CY1125223T1 (pl) |
| DK (2) | DK3400217T3 (pl) |
| EA (1) | EA036990B1 (pl) |
| ES (2) | ES2915948T3 (pl) |
| HR (2) | HRP20220673T1 (pl) |
| HU (2) | HUE058872T2 (pl) |
| IL (5) | IL318222A (pl) |
| LT (2) | LT3400217T (pl) |
| MA (2) | MA43549A (pl) |
| MX (3) | MX379544B (pl) |
| PL (2) | PL3397622T3 (pl) |
| PT (2) | PT3400217T (pl) |
| RS (2) | RS63286B1 (pl) |
| SG (4) | SG10202009723PA (pl) |
| SI (2) | SI3400217T1 (pl) |
| SM (2) | SMT202200248T1 (pl) |
| UA (2) | UA125377C2 (pl) |
| WO (2) | WO2017118639A1 (pl) |
| ZA (1) | ZA201903769B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6933322B2 (ja) * | 2016-01-04 | 2021-09-08 | メルク セローノ エス．エー． | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形 |
| RU2711615C1 (ru) * | 2019-09-12 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения эндометриоза на основании экспериментальной модели у крыс |
| JP2022548314A (ja) * | 2019-09-23 | 2022-11-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法 |
| US12426782B2 (en) | 2020-11-06 | 2025-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and temporal alignment methods for evaluation of gestational age and time to delivery |
| CA3204921A1 (en) * | 2020-12-11 | 2022-06-16 | Elise A. Olsen | Compositions and methods for inhibiting hair growth |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3835175A (en) | 1971-03-15 | 1974-09-10 | Research Corp | 9-fluorenylmethanol haloformates, carbonates and thiocarbonates |
| US3839396A (en) | 1971-07-15 | 1974-10-01 | Shionogi & Co | 9-lower alkyl-9-fluorenyl carbonates |
| US4108846A (en) | 1977-02-01 | 1978-08-22 | Hoffmann-La Roche Inc. | Solid phase synthesis with base N alpha-protecting group cleavage |
| SE430885B (sv) | 1980-03-24 | 1983-12-19 | Ferring Ab | Oxytocin-derivat |
| US4581167A (en) | 1982-01-19 | 1986-04-08 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| US4508657A (en) | 1982-01-19 | 1985-04-02 | Research Corporation | Peptide synthesis and amino acid blocking agents |
| EP0112809B1 (en) | 1982-12-21 | 1986-05-28 | Ferring AB | Vasotocin derivatives |
| US4460501A (en) | 1983-08-30 | 1984-07-17 | Research Corporation | Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides |
| US5370135A (en) * | 1993-10-13 | 1994-12-06 | Biex, Inc. | Use of estriol measurement to monitor tocolytic therapy |
| DE4434488A1 (de) * | 1994-09-14 | 1996-03-21 | Schering Ag | Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| IN188411B (pl) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| CN1444587A (zh) * | 2000-05-30 | 2003-09-24 | 奥索-麦克尼尔药品公司 | 二氢吡啶软药及相关组合物和方法 |
| GB0130677D0 (en) | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| EP1480998B1 (en) | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
| KR20040095311A (ko) | 2002-03-28 | 2004-11-12 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 프로스타글란딘 ｆ 수용체의 모듈레이터로서의 티아졸리딘카르복사미드 유도체 |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| US7521530B2 (en) * | 2002-06-11 | 2009-04-21 | Universite De Montreal | Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor |
| UA78058C2 (en) | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
| RU2005121904A (ru) * | 2002-12-12 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 2`-разветвленных нуклеозидов |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| JP2013509391A (ja) | 2009-10-30 | 2013-03-14 | グラクソ グループ リミテッド | （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態 |
| EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
| EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| CN106999497A (zh) * | 2014-06-16 | 2017-08-01 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗早产的瑞托西班 |
| AU2015283133B2 (en) | 2014-07-02 | 2019-05-16 | ObsEva SA | Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity |
| ES2716862T3 (es) | 2014-12-22 | 2019-06-17 | Ferring Bv | Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida |
| JP6933322B2 (ja) | 2016-01-04 | 2021-09-08 | メルク セローノ エス．エー． | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形 |
| US9447055B1 (en) * | 2016-01-04 | 2016-09-20 | Merck Serono S.A. | α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
-
2017
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 MX MX2018008304A patent/MX379544B/es unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Ceased
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/en not_active Ceased
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/en active Active
- 2017-01-04 KR KR1020257022032A patent/KR20250107965A/ko active Pending
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/en active Active
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/en not_active Ceased
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 MX MX2018008157A patent/MX389261B/es unknown
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 SM SM20220248T patent/SMT202200248T1/it unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/en active Pending
- 2017-01-04 CA CA3009573A patent/CA3009573A1/en active Pending
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/en active Pending
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 SM SM20220249T patent/SMT202200249T1/it unknown
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
- 2017-01-04 IL IL318222A patent/IL318222A/en unknown
- 2017-01-04 KR KR1020187018929A patent/KR102795275B1/ko active Active
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 CA CA3009576A patent/CA3009576A1/en active Pending
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
-
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
-
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
-
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
-
2022
- 2022-06-01 CY CY20221100383T patent/CY1125223T1/el unknown
- 2022-06-01 CY CY20221100384T patent/CY1125231T1/el unknown
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en not_active Abandoned
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending
-
2025
- 2025-09-04 JP JP2025147215A patent/JP2026000959A/ja active Pending
- 2025-10-22 AU AU2025256134A patent/AU2025256134A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2022009I1 (no) | Lumasiran, optionally in the form of a salt | |
| IL255002A0 (en) | Annuloplasty technologies | |
| DK3319956T3 (da) | Substituerede oxopyridinderivater | |
| LT3236972T (lt) | Antivirusiniai n4-hidroksicitidino dariniai | |
| DK3642202T3 (da) | Dihydro-pyrrolo-pyridin-derivater | |
| IL265166B (en) | Anti-influenza virus pyrimidine derivatives | |
| PL3360864T3 (pl) | Związek pirymidynowy | |
| HUE058009T2 (hu) | 1,3-Tiazol-2-il szubsztituált benzamid-származékok | |
| LT3204359T (lt) | Tetrahidroizochinolino dariniai | |
| DK4036094T3 (da) | Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse | |
| DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
| LT3402792T (lt) | Chinolin-2-ono dariniai | |
| DK3484978T3 (da) | Klare saltopløsninger med høj densitet | |
| HUE048321T2 (hu) | Karabazol származékok | |
| LT3457851T (lt) | Sobetiromo dariniai | |
| DK3231803T3 (da) | Dihydroindolizinonderivat | |
| EP3564216A4 (en) | PYRIMIDINE DERIVATIVE | |
| LT3371168T (lt) | Indolin-2-ono dariniai | |
| EP3227309C0 (en) | CRYSTALLINE DIFUCOSYLLACTOSE | |
| DK3131898T3 (da) | Fluoroalkylfluorenderivativer | |
| DK3819287T3 (da) | Amorft tapentadolphosphat | |
| PL3400217T3 (pl) | L-walinian pochodnej hydroksypropylotiazolidynokarboksyamidu, jego sól i postać krystaliczna | |
| LT3247711T (lt) | Naujos scy-078 druskos ir polimorfai | |
| DK3372589T3 (da) | Pyrimidinderivat | |
| LT3233862T (lt) | Imidazopiridazino dariniai, kaip pi3kbeta slopikliai |